Cardiac iron across different transfusion-dependent diseases

Blood Reviews

Volumn 22, Issue SUPPL. 2, 2008, Pages

  Wood, John C ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Thalassaemia major; Cardiac iron; Iron chelation therapy; Myelodysplastic syndrome; Sickle cell disease

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT;

AGRANULOCYTOSIS; ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG TRANSPORT; FERRITIN BLOOD LEVEL; HEART FUNCTION; HUMAN; IRON BALANCE; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SIDEROSIS;

ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BLOOD TRANSFUSION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; MYOCARDIUM;

EID: 57049104663     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(08)70004-3     Document Type: Review

References (50)

1. Olivieri N.F., Nathan D.G., MacMillan J.H., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331 (1994) 574-578
2. Borgna-Pignatti C., Rugolotto S., De S.P., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89 (2004) 1187-1193
3. Buja L.M., and Roberts W.C. Iron in the heart. Etiology and clinical significance. Am J Med 51 (1971) 209-221
4. Wood J.C., Enriquez C., Ghugre N., et al. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann NY Acad Sci 1054 (2005) 386-395
5. Oudit G.Y., Trivieri M.G., Khaper N., et al. Role of L-type Ca2+ channels in iron transport and iron-overloaded cardiomyopathy. J Mol Med 84 (2006) 349-364
6. Bartfay W.J., and Bartfay E. Iron-overload cardiomyopathy: evidence for a free radical-mediated mechanism of injury and dysfunction in a murine model. Biol Res Nurs 2 (2000) 49-59
7. Gabutti V., and Piga A. Results of long-term iron-chelating therapy. Acta Haematol 95 (1996) 26-36
8. Telfer P.T., Prestcott E., Holden S., et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 110 (2000) 971-977
9. Davis B.A., O'Sullivan C., Jarritt P.H., et al. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104 (2004) 263-269
10. Brittenham G.M., Griffith P.M., Nienhuis A.W., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major. N Engl J Med 331 (1994) 567-573
11. Angelucci E., Brittenham G.M., McLaren C.E., et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 343 (2000) 327-331
12. Angelucci E., Baronciani D., Lucarelli G., et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 89 (1995) 757-761
13. St Pierre T.G., Clark P.R., Chua-Anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 (2005) 855-861
14. Wood J.C. Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol 82 12 Suppl (2007) 1132-1135
15. Wood J.C., and Ghugre N. Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin 32 (2008) 85-96
16. Anderson L.J., Holden S., Davis B., et al. Cardiovascular T2- star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22 (2001) 2171-2179
17. Porter J.B. Practical management of iron overload. Br J Haematol 115 (2001) 239-252
18. Wood J.C. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 14 (2007) 183-190
19. Wood J.C., Otto-Duessel M., Aguilar M., et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 112 (2005) 535-545
20. Ghugre N.R., Enriquez C.M., Gonzalez I., et al. MRI detects myocardial iron in the human heart. Magn Reson Med 56 (2006) 681-686
21. Cheung Y.F., Chan G.C., and Ha S.Y. Effect of deferasirox (ICL670) on arterial function in patients with beta-thalassaemia major. Br J Haematol 141 (2008) 728-733
22. Li W., Coates T., and Wood J.C. Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major. Haematologica 93 (2008) 311-312
23. Tanner M.A., Galanello R., Dessi C., et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation 115 (2007) 1876-1884
24. Jensen P.D., Jensen F.T., Christensen T., et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 101 (2003) 4632-4639
25. Schafer A., Cheron R.G., Dluhy R., et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304 (1981) 319-324
26. Borgna-Pignatti C., Cappellini M.D., De Stefano P., et al. Cardiac morbidity and mortality in desferrioxamine or deferiprone treated patients with thalassaemia major. Blood 107 (2006) 3733-3737
27. Wood J.C., Tyszka J.M., Carson S., et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 103 (2004) 1934-1936
28. Wood J.C., Origa R., Agus A., et al. Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica 93 (2008) 917-920
29. Glanville J., Eleftheriou P., and Porter J.B. MRI evidence of cardiac iron accumulation in myelodysplasia and unusual anaemias. Blood 108 (2006) abstract 1553.
30. Chacko J., Pennell D.J., Tanner M.A., et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 138 (2007) 587-593
31. Konen E., Ghoti H., Goitein O., et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol 82 (2007) 1013-1016
32. Walter P.B., Fung E.B., Killilea D.W., et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 135 (2006) 254-263
33. Shah F.T., Westwood M.A., Evans P.J., et al. Discordance in MRI assessment in iron distribution and plasma NTBI between transfusionally iron loaded adults with sickle cell and thalassemia. Blood 100 (2002) abstract 668a.
34. Papanikolaou G., Tzilianos M., Christakis J.I., et al. Hepcidin in iron overload disorders. Blood 105 (2005) 4103-4105
35. Fung E.B., Harmatz P.R., Lee P.D., et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 135 (2006) 574-582
36. Smiley D., Dagogo-Jack S., and Umpierrez G. Therapy insight: metabolic and endocrine disorders in sickle cell disease. Nat Clin Pract Endocrinol Metab 4 (2008) 102-109
37. Raman S.V., Simonetti O.P., Cataland S.R., et al. Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease. Haematologica 91 (2006) 1329-1335
38. Westwood M.A., Shah F., Anderson L.J., et al. Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy. J Magn Reson Imaging 26 (2007) 564-568
39. Anderson L.J., Wonke B., Prescott E., et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360 (2002) 516-520
40. Pennell D.J., Berdoukas V., Karagiorga M., et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107 (2006) 3738-3744
41. Glickstein H., El R.B., Link G., et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108 (2006) 3195-3203
42. Wood J.C., Otto-Duessel M., Gonzalez I., et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 148 (2006) 272-280
43. Otto-Duessel M., Aguilar M., Nick H., et al. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp Hematol 35 (2007) 1069-1073
44. Vichinsky E., Onyekwere O., Porter J., et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136 (2007) 501-508
45. Piga A., Galanello R., Forni G.L., et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91 (2006) 873-880
46. Cappellini M.D., Cohen A., Piga A., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
47. Porter J., Galanello R., Saglio G., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80 (2008) 168-176
48. Porter J.B., Tanner M.A., Pennell D.J., et al. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox). Blood 106 (2005) abstract 3600.
49. Wood J., Thompson A.A., Paley C., et al. MRI t2* demonstrates reduced cardiac iron burden following moderate-to high-dose deferasirox treatment in chronically transfused beta-thalassemia patients. Haematologica 93 1 (2008) abstract 0844.
50. Taher A., Al Jefri A., Elalfy M.S., et al. Oral deferasirox (Exjade®, ICL670) is effective, with a clinically manageable safety profile, in pediatric β-thalassemia patients with high iron burden. Blood 110 (2007) abstract 2279.